Chemistry:Fosopamine
From HandWiki
Fosopamine (INN; developmental code names SIM-2055, Z-2055; also known as fosfenamine or N-methyldopamine 4-O-phosphate) is a dopamine receptor agonist of the phenethylamine and catecholamine families which was under development for the treatment of hypertension but was never marketed.[1][2] It is taken orally.[1] Fosopamine is a prodrug of epinine (N-methyldopaine) and is said to be selectively metabolized into epinine in the kidneys.[3] The drug was being developed by AstraZeneca and Zambon Group SpA.[1] It reached phase 2 clinical trials prior to the discontinuation of its development.[1]
See also
- Neurotransmitter prodrug
References
- ↑ 1.0 1.1 1.2 1.3 "Fosopamine". 7 April 1999. https://adisinsight.springer.com/drugs/800002585.
- ↑ Organic-chemical Drugs and Their Synonyms: (an International Survey). Akademie Verlag. 1994. ISBN 978-3-05-500156-7. https://books.google.com/books?id=1ghtAAAAMAAJ. Retrieved 27 February 2025.
- ↑ Advances in Prodrugs: Design and Therapeutic Applications. Elsevier. 2024. p. 296. ISBN 978-0-443-15634-2. https://books.google.com/books?id=R8TnEAAAQBAJ&pg=PA296. Retrieved 27 February 2025.
| Phenethylamines |
|
|---|---|
| Amphetamines |
|
| Phentermines |
|
| Cathinones |
|
| Phenylisobutylamines | |
| Phenylalkylpyrrolidines | |
| Catecholamines (and close relatives) |
|
| Miscellaneous |
|
0.00 ![]() ![]() ![]() ![]() (0 votes) |
